GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Total Stockholders Equity

4basebio (XTER:88Q) Total Stockholders Equity : €3.98 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Total Stockholders Equity?

4basebio's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €3.98 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. 4basebio's Book Value per Share for the quarter that ended in Jun. 2023 was €0.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. 4basebio's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.00.

4basebio Total Stockholders Equity Historical Data

The historical data trend for 4basebio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Total Stockholders Equity Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
-2.23 17.08 13.76 8.19

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Stockholders Equity Get a 7-Day Free Trial 15.62 13.76 11.06 8.19 3.98

4basebio  (XTER:88Q) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

4basebio's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.975-0)/12.3195
=0.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

4basebio's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 3.975
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4basebio Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of 4basebio's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Total Stockholders Equity
Comparable Companies
LSE:ETX LSE:AREC LSE:OBD LSE:DEST LSE:SBTX LSE:SAR LSE:FUM LSE:TRX LSE:REDX LSE:C4XD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
4BB:UK
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
Website
https://www.4basebio.com
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines